[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"penetrating-keratoplasty\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:penetrating-keratoplasty":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579011","effectiveness-of-pkp-vs-dsaek-in-terms-of-2-year-postoperative-visual-acuity-in-advanced-bpk-100579011",false,"NCT06818747","Effectiveness of PKP vs DSAEK in Terms of 2-year Postoperative Visual Acuity in Advanced BPK","Comparative Effectiveness of PKP and DSAEK in Terms of 2-year Postoperative Visual Acuity in Advanced Bullous Pseudophakic Keratopathy: a Randomised Clinical Trial","DESPEK","Inclusion Criteria:\n\n* The patient:\n\n  1. Is ≥ 50 years old.\n  2. Has advanced PBK, with a best corrected visual acuity that lies between being able to see a hand move (i.e. 2 logMAR, included) and 2\u002F10 excluded (i.e. 0.7 logMAR, excluded) and a central corneal thickness that exceeds 600 μm.\n  3. Is indicated for a corneal transplant.\n  4. Is pseudophakic.\n  5. Has provided free and informed written consent.\n  6. Is affiliated to a social security scheme.\n  7. Can be followed-up by the same investigating team during the study period.\n\nExclusion Criteria:\n\n* The patient:\n\n  1. Has a history of corneal transplant on either eye (i.e. the study surgery will be the first corneal transplant for the patient).\n  2. Has an anterior chamber lens implant or is aphakic.\n  3. Has an ocular comorbidity that will impact visual acuity recovery: exudative or advanced atrophic AMD, advanced diabetic retinopathy (macular edema), advanced glaucoma (damage to the central visual field), important sequelae of central venous thrombosis of the retina or retinal detachment, previous amblyopia.\n  4. Has a contraindication to general anesthesia.\n  5. Is deprived of freedom, or under a legal protective measure.\n  6. Is included in another clinical study.\n  7. Has a severe general condition that might lead to premature discontinuation of the trial before the end of treatment period.","ALL","50 Years",{"count":20,"type":21},334,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an open-label multicenter randomised controlled clinical trial with 2 parallel arms with a 1:1 ratio. Patients meeting the eligibility criteria will be offered to participate in the study during an ophthalmology consultation. If they agree, they are randomised into one of the 2 arms, surgery is scheduled, and baseline visual acuity, quality of life, patient satisfaction, pain level, and central corneal thickness are recorded (inclusion visit). The following visits involve: the corneal transplant procedure (DSAEK or PKP depending on the randomisation) and follow-up visits at 1, 6, 12, and 24 months. At each visit, visual acuity, patient satisfaction, pain level and complications will be determined. At 6, 12, and 24 months, endothelial cell density, central corneal thickness and required optical correction will be measured. At 12 and 24 months, quality of life, will also be determined.",[27,28],"Bullous Pseudophakic Keratopathy","Penetrating Keratoplasty",[30,31],"Best corrected monocular visual acuity","Quality of life","RECRUITING","2026-06-20",{"date":35,"type":36},"2026-06-24","ACTUAL",{"date":38,"type":36},"2025-05-21",{"date":40,"type":21},"2029-08-21",{"name":42,"class":43},"Centre Hospitalier Régional Metz-Thionville","OTHER",11,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100587291","phase-1-subconjunctival-humira-for-boston-keratoprosthesis-100587291","NCT06926478","Subconjunctival Humira for Boston Keratoprosthesis","Clinical Trial to Evaluate Short-term Safety of Subconjunctival Adalimumab in Combination With Type 1 Boston Keratoprosthesis Implantation","Inclusion Criteria:\n\n* Age 18 years or older\n* Individuals eligible for keratoprosthesis surgery, as determined by standard-of-care eligibility criteria\n* Patients with poor prognosis for corneal transplantation, severe corneal opacity and\u002For vascularization\n* Patients with vision worse than 20\u002F200 in the eligible eye, and contralateral eye with vision less than 20\u002F40\n* Patients with intact nasal light projection\n* Willing and able to comply with study plan for the full duration of the study\n* Willing and able to sign a written informed consent\n\nExclusion Criteria:\n\n* Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-# release assay \\[IGRA\\] test, such as Quantiferon-gold)\n* Untreated active hepatitis B or C infection.\n* Ocular or periocular malignancy and\u002For infection\n* Inability to wear contact lens\n* Pregnancy (positive pregnancy test) or lactating\n* Participation in another interventional study at the time of screening\n* Any of the following baseline lab values\n\n  1. White blood count \\\u003C3500 cells per microliter\n  2. Platelets \\\u003C100,000 per microliter\n  3. Hematocrit \\\u003C30%\n  4. AST or ALT \\>1.5X upper limit normal value\n* Multiple sclerosis or other demyelinating disease\n* Severe uncontrolled infection\n* Moderate to severe heart failure (NYHA class III\u002FIV)\n* Active malignancy\n* History of adalimumab intolerance\n* Pregnancy or lactation\n* Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures.\n* As judged by the investigator any patients that are questionable for their suitability in the study","18 Years",{"count":54,"type":21},8,[56],"PHASE1","This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.",[28,59,60,61],"Multiple Graft Failure","Ocular Cicatricial Pemphigoid","Stevens-Johnson Syndrome",[63,64,65,66],"Kpro","Boston Kpro","Keratoprosthesis","Type-1 Boston Kpro","NOT_YET_RECRUITING","2026-03-23",{"date":70,"type":36},"2026-03-27",{"date":72,"type":21},"2026-06-01",{"date":74,"type":21},"2028-06-01",{"name":76,"class":43},"Massachusetts Eye and Ear Infirmary",1]